Perclose, Inc.
Perclose, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Perclose, Inc..
Perclose, Inc. is a company.
Key people at Perclose, Inc..
Key people at Perclose, Inc..
Perclose, Inc. was a medical device company that developed suture-mediated arterial closure devices to seal femoral artery access sites after diagnostic or interventional catheterization procedures. It served interventional cardiologists, vascular surgeons, and cath lab teams, solving the problem of achieving rapid, secure hemostasis without manual compression, which reduces time to ambulation, discharge, and complications like bleeding or pseudoaneurysms.[2][3][4][5] Acquired by Abbott Laboratories in a $680 million stock-for-stock deal around 2001 (expected year-end completion), Perclose's technology evolved into flagship products like Perclose ProGlide and the next-generation Perclose ProStyle, now part of Abbott Vascular's portfolio with broad indications for 5-21F arterial and 5-24F venous sheaths.[2][3][4][5]
Perclose, Inc. was founded in Redwood City, California, as a pioneer in the emerging arterial closure device market, which was less than five years old at the time of its acquisition and growing at over 40% annually amid rising catheterization procedures (over seven million worldwide, though under 20% used closure devices).[2] The company gained early traction with suture-based systems like the Techstar XL, though it faced a voluntary recall in 2001 due to a manufacturing issue with needle deployment, which was quickly resolved.[2] Abbott Laboratories acquired Perclose to bolster its cardiovascular portfolio, integrating and advancing the technology into systems like ProGlide and ProStyle.[2][3][4]
Perclose's technology stood out in vascular closure through suture-mediated closure and repair (SMCR), paralleling surgical gold standards while enabling percutaneous use:
(Note: A conflicting source lists Perclose in custom software/IT services with 500-999 employees and $250-500M revenue, but this appears erroneous given consistent medtech evidence.[1][2][3][4][5])
Perclose rode the explosive growth of minimally invasive cardiovascular interventions, where closure devices addressed a key bottleneck in over seven million annual catheterizations by enabling faster recovery and repeat access.[2] Timing was ideal as the market surged >40% CAGR in the early 2000s, driven by rising procedures for diagnostics and stents.[2] Abbott's acquisition amplified its influence, embedding Perclose tech into global standards like ProGlide/ProStyle, which promote vessel healing and reduce complications amid trends toward larger sheaths and venous closures.[3][4][5] This shaped the ecosystem by setting benchmarks for suture-based systems over collagen plugs, influencing competitors and expanding cath lab efficiency.
Perclose's legacy endures through Abbott's ongoing innovations like ProStyle, with enhancements for challenging anatomy signaling adaptation to complex procedures (e.g., TAVR, EVAR).[3] Rising minimally invasive interventions and venous access needs will drive demand, potentially expanding indications or AI-guided deployment. As cath volumes grow with aging populations, Perclose tech's role in enabling same-day discharges could solidify Abbott's dominance, evolving from acquisition target to ecosystem cornerstone.[2][3][4][5]
